ProPhase Labs, Inc. provided an update regarding its progress and development strategy for Linebacker-1 (LB-1), a small molecule, multi-kinase inhibitor that is being developed by the Company's wholly owned subsidiary, ProPhase BioPharma, Inc. ("PBIO"), as a potential unique therapy option for several poor prognosis cancers. Harvard scientists at the Dana Farber Cancer Institute, in two separate lung and colon cancer clonogenic models, have successfully demonstrated Linebacker's ability to inhibit cancer cell growth, an exciting development for the polyphenol compound. AH549 lung cancer cells completely lost the ability to proliferate over a 2-week period of treatment, while the HT29 colon cancer cells also saw significant inhibitory results.

In the AH549 model, the Linebacker monotherapy showed zero cell proliferation, while the combination therapy showed some proliferation, and the control group showed massive cell proliferation. Also observed were synergies between Linebacker and low doses of frontline chemotherapeutic agents such as Doxorubicin in the colon cancer model. The initial observation is that Linebacker may have enhanced utlity as a combination therapy in cancer types that respond well or moderately well to Doxorubicin and should also be considered as a potential monotherapy for myriad cancers that previously showed no response.

With proof-of-principle demonstrated, the ProPhase team is moving forward with in-depth cancer modeling to precisely hone-in on optimal clinical pathways for development.